Literature DB >> 23594477

Implantable arterial port-related bloodstream infection in patients with primary or metastatic hepatic malignancies.

Hitoshi Honda1, Yasuo Sakurai, Jong-Hon Kang, Tadahiro Nakamura, Hirotaka Matsuura, David K Warren.   

Abstract

The incidence of implantable arterial post-related bloodstream infections (IAP-RBSI) among patients with unresectable hepatic malignancies is not well defined. We reviewed the 9-year incidence of implantable arterial post-related bloodstream infections in patients with hepatic malignancies, at a tertiary care center in Japan. The incidence was 1.9 infections per 10,000 catheter-days.
Copyright © 2013 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  Hepatic malignancies; Implantable arterial port; Port-related bloodstream infection

Mesh：

Year:  2013        PMID： 23594477      PMCID： PMC4689132          DOI： 10.1016/j.ajic.2013.01.018

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN： 0196-6553            Impact factor:   2.918


  10 in total

1.  Single-lumen subcutaneous ports inserted by interventional radiologists in patients undergoing chemotherapy: incidence of infection and outcome of attempted catheter salvage.

Authors:  D Kuizon; S M Gordon; B L Dolmatch
Journal:  Arch Intern Med       Date:  2001-02-12

Review 2.  Hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

Review 3.  The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies.

Authors:  Dennis G Maki; Daniel M Kluger; Christopher J Crnich
Journal:  Mayo Clin Proc       Date:  2006-09       Impact factor: 7.616

4.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.

Authors:  Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

5.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

6.  Hepatocellular carcinoma - United States, 2001-2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-07       Impact factor: 17.586

7.  Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.

Authors:  N Kemeny; Y Huang; A M Cohen; W Shi; J A Conti; M F Brennan; J R Bertino; A D Turnbull; D Sullivan; J Stockman; L H Blumgart; Y Fong
Journal:  N Engl J Med       Date:  1999-12-30       Impact factor: 91.245

8.  A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies.

Authors:  Archie N Tse; Nian Wu; Dina Patel; Dana Haviland; Nancy Kemeny
Journal:  Cancer Chemother Pharmacol       Date:  2009-02-17       Impact factor: 3.333

9.  Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66.

Authors:  Steven R Alberts; Mark S Roh; Michelle R Mahoney; Michael J O'Connell; David M Nagorney; Lawrence Wagman; Thomas C Smyrk; Timothy L Weiland; Lily Lau Lai; Roderich E Schwarz; Roy Molina; Todor Dentchev; John S Bolton
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

10.  Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a Phase II-study and historical comparison with the surgical approach.

Authors:  Bert Hildebrandt; Maciej Pech; Annett Nicolaou; Jan M Langrehr; Jacek Kurcz; Birgit Bartels; Alexandra Miersch; Roland Felix; Peter Neuhaus; Hanno Riess; Bernd Dörken; Jens Ricke
Journal:  BMC Cancer       Date:  2007-04-24       Impact factor: 4.430
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.